Watch on YouTube – Watch on Rumble – Watch on Vimeo

Kenton Crowley

Kenton Crowley is a Diplomate of the American Academy of Anti-Aging Medicine. He received his Doctor of Pharmacy from University of California, San Francisco and completed his residency with Kaiser Permanente in Los Angeles, CA. He completed his Fellowship in Genomic, Metabolic and Nutritional Medicine in 2011. Dr. Crowley currently is the Chief Medical Officer for Farm to Farma Inc. in Reno, NV., the Patient Care Corp. in Huntington Beach, CA. and President of Crowley Consultants Inc. in Temecula, CA. He is an expert in Lifestyle Medicine, working with patients & physicians incorporating cannabis in disease state treatment and symptoms management, whether as a primary treatment or complementary to traditional and/or other modalities.

Gavin Chandler

Gavin Chandler is the Chief Executive Officer of Trokie, a position he has held since October 2021.  Gavin builds enterprise value in early and mid-stage companies in diverse fields by leveraging his broad skills for business development, financial innovation, team building, and operations. Gavin has held executive roles in diverse fields including biotechnology, energy, big data, real estate services, and transportation safety. He’s also co-authored patents and managed patent prosecution in the fields of vehicle safety, gaming, biotechnology, environmental engineering, and genomics.

Gavin earned his B.S. in Biochemistry, Cum Laude, from the University of Nevada. He received his formal training in finance through the CFA program, earning his CFA Charter in 2007. Gavin has been a Board member of the CFA Society of Nevada since 2014. Gavin lives with his wife and daughter in Reno, Nevada.

• Introduction to Trochee’s Phytocannabinoid Supplementation 0:06
  • Dr. Barrett introduces the episode, continuing a discussion with Kenton Crawley and Gavin Chandler from Trochee about their phytocannabinoid supplementation.
  • Speaker 3 explains the patented orally dissolving Troche, highlighting its pharmaceutical elegance and temperature sensitivity.
  • The Troche is designed to minimize saliva production for rapid onset of action, typically within 5 to 15 minutes.
  • Dr. Barrett humorously asks if swallowing the Troche will result in a different coin, leading to a light-hearted response about transmutation.
• Dr. Barrett’s Personal Experience with Trochee 3:52
  • Dr. Barrett shares his personal n of one study, starting with a low dosage and gradually increasing to find the best dosing schedule.
  • He finds the best effect is to take a broad-spectrum Troche in the late afternoon for relaxation and another nighttime version with melatonin before bed.
  • Dr. Barrett emphasizes the calming effect of the Troche, comparing it to an ultimate cocktail without the negative effects of ethanol.
  • He discusses the importance of measuring various aspects of sleep, including latency, deep sleep, REM, and overall sleep scores.
• Data Analysis and Results from Trochee Tracker 5:19
  • Dr. Barrett reviews the data from the Trochee Tracker, focusing on sleep latency and its significant improvement.
  • He notes a dramatic reduction in sleep latency by almost 50%, with some fluctuations due to international travel and meetings.
  • Dr. Barrett highlights the consistency of deep sleep stages and overall sleep scores, despite the travel-induced disruptions.
  • He emphasizes the importance of sleep hygiene and the potential for significant improvement in sleep quality.
• Impact on Stress and Well-being 15:23
  • Dr. Barrett discusses the dramatic reduction in stress scores and the anxiolytic effect of the Trochee.
  • Gavin mentions a 14% improvement in perceived stress scale and a 23% improvement in final scores, comparing these results to clinical trials.
  • The discussion includes the WHO five-well-being index and its use in measuring well-being and quality of life.
  • Dr. Barrett transitions to Gavin for a deeper dive into the metrics and data from the Trochee Tracker.
• Clinical Trial Results and Comparative Analysis 16:19
  • Gavin presents data from the ACEs study, a multi-brand open-label trial on the real-world effects of hemp extracts.
  • The study involved 13 national brands, including Trochee, and measured well-being, quality of life, sleep, physical discomfort, and perceived stress.
  • Trochee’s Rapid Relief tabs showed significant improvements, with 83% of participants experiencing a significant improvement in well-being.
  • The study demonstrated that Trochee’s low-dose, oral mucosal absorption method was effective, even compared to higher-dose products.
• Real-World Sleep Trial and Additional Findings 18:39
  • Gavin discusses the real-world sleep trial, focusing on the nighttime formulation of Trochee’s Rapid Relief tabs.
  • The trial involved 213 participants, with primary endpoints in sleep quality and sleep time, and secondary endpoints in quality of life, physical discomfort, and feelings of anxiousness.
  • The nighttime formulation showed a 40% improvement in sleep disturbance scores and a 32% improvement in feelings of anxiousness.
  • Participants reported an average of 56 minutes more sleep per night and a clinically meaningful improvement in sleep scores.
• Support for Clinicians and Patients 37:36
  • Gavin explains Trochee’s support for clinicians, including the Trochee Clinician of Excellence program and custom landing pages for patient engagement.
  • The program includes in-office signage, digital brochures, and QR codes to track patient progress and provide feedback to clinicians.
  • Trochee Tracker is a mobile assessment tool that allows patients to establish a baseline for well-being, stress, sleep disturbance, and physical discomfort.
  • The system integrates biometric devices like the Apple Health suite, Fitbit, and Garmin to capture and overlay data, providing a comprehensive view of patient health.
• Network Affiliate Programs and Clinician Resources 43:53
  • Gavin introduces the network affiliate programs, designed to support large groups and associations of clinicians.
  • The programs offer special pricing on Trochee’s services and content, helping clinicians implement Trochee in their practice.
  • Dr. Barrett emphasizes the importance of patient biometric measurement for compliance with treatment plans.
  • Gavin highlights the starter package for clinicians, including a product starter kit, a one-year subscription to Trochee Tracker, and a subscription to the Cannabis and Cannabinoid Research Journal.
• Conclusion and Final Thoughts 46:46
  • Dr. Barrett thanks Gavin and Kent for their insights and contributions to the discussion.
  • Gavin expresses appreciation for the collaboration and the positive impact of Dr. Barrett’s practice on Trochee’s research.
  • Dr. Barrett encourages clinicians and patients to get involved with Trochee and take advantage of the support and resources available.
  • The episode concludes with a message from the sponsor, Approved Medical Solutions, promoting their nitric oxide supplementation products.